Statins for primary prevention of CVD: To start or not to start?

Resources

1. Ioannidis JPA. Inconsistent guideline recommendations for cardiovascular prevention and the debate about zeroing in on and zeroing LDL-C levels with PCSK9 inhibitors. JAMA. 2017;318:419-420. Available at: https://jamanetwork.com/journals/jama/fullarticle/2645741.
2. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2014;63:2889-2934. Available at: http://www.sciencedirect.com/science/article/pii/S0735109713060282?via%3Dihub.
3. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;316:1997-2007. Available at: https://jamanetwork.com/journals/jama/fullarticle/2584058.
4. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999-3058. Available at: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehw272.
5. Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32:1263-1282. Available at: http://www.onlinecjc.ca/article/S0828-282X(16)30732-2/fulltext.
6. Pagidipati NJ, Navar AM, Mulder H, et al. Comparison of recommended eligibility for primary statin therapy based on the US Preventive Services Task Force recommendations vs the ACC/AHA guidelines. JAMA. 2017;317:1563-1567. Available at: https://jamanetwork.com/journals/jama/fullarticle/2618621.